Neurogene Inc.

US$25.31As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:NGNEHealthcare
Country USA
PE (Fwd) •••
TSR 3Y CAGR 9.80%
Div yield —
ROE (45.32%)
Biotechnology
Beta (5Y) 2.10
PE TTM —
TSR TTM (26.12%)
Mkt cap US$506.5M
ROIC (29.73%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$32
25.39%
(58.08%)
Hold 10|9|6|1|9
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.32
0.33
0.36
0.37
33.89%
26.14%
38.95%
29.09%
Revenue$M
24.32
23.99
24.52
25.75
1.35%
(0.76%)
1.89%
4.60%
Peers (US$506.5M)
Cap (US$)
PE
503.9M
—
506.5M
66.46x
Capital
TTM
5Y
10Y
Leveragex
8.644
0.952
0.848
EBIT/Intx
0.605
1.518
1.446
Own earn%
(16.69)
225.82
196.24
Sh yield%
33.38
14.05
13.78
Owners
Insiders/Inst%
7.17
78.62
Short interest%
0.98
SBC / revenue%
0.92
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
8
Op margin range%
12–26
$1 testx
0.8
Incr. ROIC%
5